gyre therapeutics inc - GYRE
GYRE
Close Chg Chg %
7.69 0.01 0.13%
Pre-Market
7.70
+0.01 (0.13%)
Volume: 22.12K
Last Updated:
Jan 15, 2026, 4:00 PM EDT
Company Overview: gyre therapeutics inc - GYRE
GYRE Key Data
| Open $7.65 | Day Range 7.56 - 7.80 |
| 52 Week Range 6.11 - 13.73 | Market Cap $698.95M |
| Shares Outstanding 90.89M | Public Float 11.75M |
| Beta 2.44 | Rev. Per Employee N/A |
| P/E Ratio 204.46 | EPS $0.07 |
| Yield 0.00% | Dividend $0.24 |
| EX-DIVIDEND DATE Jan 13, 2023 | SHORT INTEREST N/A |
| AVERAGE VOLUME 92.04K |
GYRE Performance
| 1 Week | 4.05% | ||
| 1 Month | 7.99% | ||
| 3 Months | -7.23% | ||
| 1 Year | -29.68% | ||
| 5 Years | -92.14% |
GYRE Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
3
Full Ratings ➔
About gyre therapeutics inc - GYRE
Gyre Therapeutics, Inc. operates as a biopharmaceutical company. It is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis). The firm operates through the BC and Gyre segments. The company was founded on March 7, 1997 and is headquartered in San Diego, CA.
GYRE At a Glance
Gyre Therapeutics, Inc.
12770 High Bluff Drive
San Diego, California 92130
| Phone | 1-619-949-3681 | Revenue | 105.76M | |
| Industry | Pharmaceuticals: Major | Net Income | 12.09M | |
| Sector | Health Technology | Employees | 5 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
GYRE Valuation
| P/E Current | 204.462 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 251.559 |
| Price to Sales Ratio | 11.704 |
| Price to Book Ratio | 16.493 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 70.032 |
| Enterprise Value to Sales | 11.798 |
| Total Debt to Enterprise Value | 0.001 |
GYRE Efficiency
| Revenue/Employee | 21,151,400.00 |
| Income Per Employee | 2,417,000.00 |
| Receivables Turnover | 3.628 |
| Total Asset Turnover | 0.874 |
GYRE Liquidity
| Current Ratio | 3.32 |
| Quick Ratio | 2.995 |
| Cash Ratio | 1.367 |
GYRE Profitability
| Gross Margin | 96.327 |
| Operating Margin | 15.346 |
| Pretax Margin | 21.954 |
| Net Margin | 11.427 |
| Return on Assets | 9.99 |
| Return on Equity | 21.577 |
| Return on Total Capital | 18.616 |
| Return on Invested Capital | 21.37 |
GYRE Capital Structure
| Total Debt to Total Equity | 2.524 |
| Total Debt to Total Capital | 2.462 |
| Total Debt to Total Assets | 1.274 |
| Long-Term Debt to Equity | 1.398 |
| Long-Term Debt to Total Capital | 1.363 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Gyre Therapeutics Inc - GYRE
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 7.34M | 794.00K | 113.45M | 105.76M | |
Sales Growth
| -64.97% | -89.18% | +14,188.41% | -6.78% | |
Cost of Goods Sold (COGS) incl D&A
| 7.67M | 1.03M | 4.64M | 3.88M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 290.00K | 230.00K | 1.11M | 1.59M | |
Depreciation
| 290.00K | 230.00K | 1.04M | 1.55M | |
Amortization of Intangibles
| - | - | 74.00K | 38.00K | - |
COGS Growth
| -17.54% | -86.60% | +350.97% | -16.22% | |
Gross Income
| (332.00K) | (234.00K) | 108.81M | 101.87M | |
Gross Income Growth
| -102.85% | +29.52% | +46,601.71% | -6.38% | |
Gross Profit Margin
| -4.52% | -29.47% | +95.91% | +96.33% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 83.39M | 29.16M | 89.60M | 85.64M | |
Research & Development
| 64.57M | 12.20M | 13.78M | 12.02M | |
Other SG&A
| 18.82M | 16.96M | 75.82M | 73.62M | |
SGA Growth
| +20.83% | -65.03% | +207.25% | -4.42% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| 4.17M | 36.22M | 95.06M | (7.17M) | |
EBIT after Unusual Expense
| (87.89M) | (65.62M) | (75.85M) | 23.40M | |
Non Operating Income/Expense
| (39.00K) | 57.72M | (1.11M) | (178.00K) | |
Non-Operating Interest Income
| 39.00K | 537.00K | 1.04M | 1.55M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | - | - | - | - |
Interest Expense Growth
| - | - | - | - | - |
Gross Interest Expense
| - | - | - | - | - |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (87.93M) | (7.89M) | (76.97M) | 23.22M | |
Pretax Income Growth
| -56.35% | +91.02% | -874.98% | +130.17% | |
Pretax Margin
| -1,198.32% | -994.21% | -67.84% | +21.95% | |
Income Tax
| - | 348.00K | 8.52M | 5.32M | |
Income Tax - Current - Domestic
| - | 348.00K | 6.00K | 2.00K | |
Income Tax - Current - Foreign
| - | - | 9.34M | 6.32M | - |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | (834.00K) | (1.00M) | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (87.93M) | (8.24M) | (85.48M) | 17.90M | |
Minority Interest Expense
| - | - | 7.45M | 5.81M | - |
Net Income
| (87.93M) | (8.24M) | (92.93M) | 12.09M | |
Net Income Growth
| -56.35% | +90.63% | -1,027.55% | +113.00% | |
Net Margin Growth
| -1,198.32% | -1,038.04% | -81.92% | +11.43% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (87.93M) | (8.24M) | (92.93M) | 12.09M | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (87.93M) | (8.24M) | (92.93M) | 12.09M | |
EPS (Basic)
| -43.0467 | -3.9191 | -1.4117 | 0.142 | |
EPS (Basic) Growth
| +2.13% | +90.90% | +63.98% | +110.06% | |
Basic Shares Outstanding
| 2.04M | 2.10M | 65.83M | 85.09M | |
EPS (Diluted)
| -43.0467 | -3.9191 | -1.4117 | 0.0481 | |
EPS (Diluted) Growth
| +2.13% | +90.90% | +63.98% | +103.41% | |
Diluted Shares Outstanding
| 2.04M | 2.10M | 65.83M | 102.29M | |
EBITDA
| (83.44M) | (29.17M) | 20.33M | 17.82M | |
EBITDA Growth
| -45.79% | +65.04% | +169.69% | -12.35% | |
EBITDA Margin
| -1,137.04% | -3,673.30% | +17.92% | +16.85% |
Snapshot
| Average Recommendation | BUY | Average Target Price | 19.00 | |
| Number of Ratings | 3 | Current Quarters Estimate | 0.075 | |
| FY Report Date | 03 / 2026 | Current Year's Estimate | 0.183 | |
| Last Quarter’s Earnings | 0.06 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 0.16 | Next Fiscal Year Estimate | 0.09 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 2 | 2 | 3 | 2 |
| Mean Estimate | 0.08 | 0.05 | 0.18 | 0.09 |
| High Estimates | 0.09 | 0.10 | 0.43 | 0.17 |
| Low Estimate | 0.06 | 0.00 | 0.02 | 0.01 |
| Coefficient of Variance | 28.28 | 141.42 | 118.54 | 125.71 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 3 | 3 | 3 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 0 | 0 | 0 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Gyre Therapeutics Inc - GYRE
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Gyre Therapeutics Inc - GYRE
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Jan 12, 2026 | Ruo Yu Chen Chief Financial Officer | 50,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 12, 2026 | Ping Zhang Director | 100,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| May 21, 2025 | Song Jiang Ma President; Director | 2,816,824 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $11.31 per share | 31,858,279.44 |
| May 21, 2025 | Song Jiang Ma President; Director | 2,814,824 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $11.11 per share | 31,272,694.64 |
| Mar 24, 2025 | Songjiang Ma President; Director | 2,827,018 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $10.13 per share | 28,637,692.34 |
| Mar 24, 2025 | Songjiang Ma President; Director | 2,825,018 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $10.09 per share | 28,504,431.62 |
| Mar 21, 2025 | GNI Group Ltd. President; Director | 2,829,260 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $12.09 per share | 34,205,753.40 |
| Mar 21, 2025 | GNI Group Ltd. President; Director | 2,829,018 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $10.24 per share | 28,969,144.32 |
| Mar 12, 2025 | GNI Group Ltd. President; Director | 2,841,260 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $10.13 per share | 28,781,963.80 |
| Mar 12, 2025 | GNI Group Ltd. President; Director | 2,839,260 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $10.14 per share | 28,790,096.40 |
| Mar 12, 2025 | Weiguo Ye Chief Operating Officer | 300,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 26, 2025 | Songjiang Ma President; Director | 2,859,447 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $10.6 per share | 30,310,138.20 |
| Feb 26, 2025 | Songjiang Ma President; Director | 2,859,260 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $11.52 per share | 32,938,675.20 |